Boston Scientific Corp. Price Target Raised to $12.00 at Jefferies Group (BSX)
Analysts at Jefferies Group upped their price objective on shares of Boston Scientific Corp. (NYSE:BSX) to $12.00 in a research report issued to clients and investors on Friday, Analyst Ratings Net reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s target price points to a potential upside of 3.27% from the stock’s previous close.
A number of other firms have also recently commented on BSX. Analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, October 9th. They now have a $12.00 price target on the stock. Separately, analysts at CL King downgraded shares of Boston Scientific Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. Finally, analysts at Barclays reiterated a “buy” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, September 4th. They now have a $12.00 price target on the stock. Fifteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $9.99.
Shares of Boston Scientific Corp. (NYSE:BSX) traded up 0.69% on Friday, hitting $11.62. 16,792,788 shares of the company’s stock traded hands. Boston Scientific Corp. has a one year low of $5.04 and a one year high of $12.16. The stock has a 50-day moving average of $11. and a 200-day moving average of $9.12. The company’s market cap is $15.604 billion.
Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Boston Scientific Corp. will post $0.44 EPS for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.